LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Inicio・Lista de Acciones・Novo Nordisk A-S

Novo Nordisk A-S

Cerrado

SectorSanidad

46.01 0.46

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

45.8

Máximo

46.13

Métricas clave
By Trading Economics
Ingresos	6.9B 27B
Ventas	4.2B 79B
P/B Media del Sector	12.162 49.8
Rentabilidad por dividendo	4.11
Margen de beneficios	33.977
Empleados	68,794
EBITDA	3.5B 37B

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	-10.57% downside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	4.11% 2.25%

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-65B 197B
Apertura anterior	45.55
Cierre anterior	46.01

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

62.63 / 69.23 Soporte y Resistencia

Novo Nordisk A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 may 2026, 07:30 UTC

Ganancias

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6 may 2026, 06:19 UTC

Ganancias

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

7 may 2026, 09:30 UTC

Ganancias

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 may 2026, 12:36 UTC

Ganancias

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 may 2026, 10:53 UTC

Acciones populares

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 may 2026, 10:12 UTC

Ganancias

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 may 2026, 09:58 UTC

Ganancias

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6 may 2026, 09:35 UTC

Acciones populares

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 may 2026, 08:13 UTC

Charlas de Mercado

Ganancias

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6 may 2026, 07:43 UTC

Charlas de Mercado

Ganancias

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6 may 2026, 07:00 UTC

Ganancias

Novo Nordisk Shares Rise 5.5% After 1Q Results

6 may 2026, 06:34 UTC

Ganancias

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6 may 2026, 06:26 UTC

Ganancias

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6 may 2026, 06:26 UTC

Ganancias

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6 may 2026, 06:24 UTC

Ganancias

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6 may 2026, 06:20 UTC

Ganancias

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6 may 2026, 06:19 UTC

Ganancias

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6 may 2026, 06:13 UTC

Ganancias

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6 may 2026, 06:13 UTC

Ganancias

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6 may 2026, 06:12 UTC

Ganancias

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6 may 2026, 05:43 UTC

Ganancias

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6 may 2026, 05:42 UTC

Ganancias

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6 may 2026, 05:40 UTC

Ganancias

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

6 may 2026, 05:40 UTC

Ganancias

Novo Nordisk 1Q Op Margin 61.6%

6 may 2026, 05:39 UTC

Ganancias

Novo Nordisk 1Q Gross Margin 85.9%

6 may 2026, 05:39 UTC

Ganancias

Novo Nordisk 1Q Wegovy Injectable Sales Rose 12% at CER To DKK 18.24B, Consensus Saw DKK16.85B

6 may 2026, 05:38 UTC

Ganancias

Novo Nordisk 1Q Ozempic Drug Sales Fell 8% at CER To DKK27.83B, Consensus Saw DKK26.4B

6 may 2026, 05:36 UTC

Ganancias

Novo Nordisk: Analysts Saw 1Q Net Profit At DKK23.3B

6 may 2026, 05:36 UTC

Ganancias

Novo Nordisk 1Q Net Pft DKK48.56B

6 may 2026, 05:36 UTC

Ganancias

Novo Nordisk: Analysts Saw 1Q Op Pft at DKK49.11B

Comparación entre iguales

Cambio de precio

Novo Nordisk A-S previsión

Precio Objetivo

By TipRanks

-10.57% descenso

Estimación a 12 Meses

Media 41.2 USD -10.57%

Máximo 47 USD

Mínimo 36 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Novo Nordisk A-S Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

62.63 / 69.23Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.